Indivior Pharmaceuticals, Inc. cotiza a 35.42 USD y tiene una capitalización bursátil de $4.2B. En los últimos 12 meses ha facturado $1.3B con un margen de flujo de caja libre del -7.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat su…
| Periodo | 2026-11 | 2026-08 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $1.15 | $0.96 | $0.82 |
| Estimado | $1.12 | $0.92 | $0.66 | $0.67 |
| Sorpresa | — | +25.0% | +45.5% | +22.4% |
| Métrica | INDV | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 80.2% | 57.0% | +23.2% |
| Operating Margin | 21.1% | -38.6% | +59.8% |
| Net Margin | 16.9% | -33.6% | +50.5% |
| FCF Margin | -7.5% | -13.9% | +6.3% |
| ROE | — | -40.4% | — |
| ROA | 17.5% | -32.0% | +49.5% |
| Current Ratio | 0.71 | 2.84 | -2.13 |
| Debt / Equity | -2.96 | 0.28 | -3.24 |